BIOMAT Database Logo BIOMAT Database Logo

The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. 1991

D K Imagawa, and J M Millis, and P Seu, and K M Olthoff, and J Hart, and E Wasef, and R A Dempsey, and S Stephens, and R W Busuttil
Department of Surgery and Pathology, University of California, Los Angeles School of Medicine 90024.

We have previously demonstrated that TNF-alpha levels are elevated in liver transplant patients experiencing acute rejection. In addition, prophylactic administration of anti-TNF-alpha or anti-TNF-beta antibodies prolonged graft survival in a rat heterotopic cardiac transplant model. This experiment was designed to evaluate anti-TNF therapy in the treatment of acute allograft rejection. Heterotopic cardiac transplants were performed using Buffalo donors and Lewis recipients. Histologic sections of transplanted grafts from untreated animals revealed significant rejection at day 4 with terminal rejection occurring on day 10.8 +/- 0.4. Animals in the experimental groups received antirejection therapy from postoperative days 4-13. Treatment with cyclosporine at 2 mg/kg/day prolonged graft survival to 16.5 +/- 2.0 days (P = 0.01 versus controls). Administration of polyclonal anti-TNF-alpha in combination with polyclonal anti-TNF-beta increased graft survival to 14.6 +/- 0.4 days (P less than 0.001 versus controls). Use of a monoclonal anti-TNF-alpha antibody was even more effective, with graft survival of 17.4 +/- 0.7 days (P less than 0.001 versus controls). Combination immunotherapy with monoclonal anti-TNF-alpha in conjunction with CsA extended survival to greater than 30 days. In contrast, recombinant TNF-alpha (5 micrograms/day, i.p.) markedly accelerated the time to graft failure (7.4 +/- 0.2 days, P less than 0.001 versus controls). Examination of explanted graft tissue on postoperative day 9 from animals treated with anti-TNF showed decreased mononuclear cell infiltrate when compared to untreated animals. Treatment with TNF-alpha markedly increased the inflammatory process. These results suggest that TNF may play a role in the pathogenesis of acute rejection.

UI MeSH Term Description Entries
D008297 Male Males
D011915 Rats, Inbred BUF An inbred strain of rat that is used for cancer research, particularly the study of CARCINOGENESIS Rats, Inbred Buffalo,Rats, BUF,BUF Rat,BUF Rat, Inbred,BUF Rats,BUF Rats, Inbred,Buffalo Rats, Inbred,Inbred BUF Rat,Inbred BUF Rats,Inbred Buffalo Rats,Rat, BUF,Rat, Inbred BUF
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D014184 Transplantation, Homologous Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals. Transplantation, Allogeneic,Allogeneic Grafting,Allogeneic Transplantation,Allografting,Homografting,Homologous Transplantation,Grafting, Allogeneic
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D016027 Heart Transplantation The transference of a heart from one human or animal to another. Cardiac Transplantation,Grafting, Heart,Transplantation, Cardiac,Transplantation, Heart,Cardiac Transplantations,Graftings, Heart,Heart Grafting,Heart Graftings,Heart Transplantations,Transplantations, Cardiac,Transplantations, Heart

Related Publications

D K Imagawa, and J M Millis, and P Seu, and K M Olthoff, and J Hart, and E Wasef, and R A Dempsey, and S Stephens, and R W Busuttil
Anti-tumor necrosis factor alpha serum prolongs heart allograft survival in rats.
February 1991, Transplantation proceedings,
D K Imagawa, and J M Millis, and P Seu, and K M Olthoff, and J Hart, and E Wasef, and R A Dempsey, and S Stephens, and R W Busuttil
Evidence inconsistent with a role for tumor necrosis factor in tumor allograft rejection.
January 1993, Transplantation,
D K Imagawa, and J M Millis, and P Seu, and K M Olthoff, and J Hart, and E Wasef, and R A Dempsey, and S Stephens, and R W Busuttil
The role of tumor necrosis factor in allograft rejection.
December 1993, Hiroshima journal of medical sciences,
D K Imagawa, and J M Millis, and P Seu, and K M Olthoff, and J Hart, and E Wasef, and R A Dempsey, and S Stephens, and R W Busuttil
Treatment with monoclonal anti-IL2 antibody prolongs cardiac allograft survival in rats.
October 1987, Transplantation proceedings,
D K Imagawa, and J M Millis, and P Seu, and K M Olthoff, and J Hart, and E Wasef, and R A Dempsey, and S Stephens, and R W Busuttil
Preconditioning with ozone abrogates acute rejection and prolongs cardiac allograft survival in rats.
May 2008, Transplantation proceedings,
D K Imagawa, and J M Millis, and P Seu, and K M Olthoff, and J Hart, and E Wasef, and R A Dempsey, and S Stephens, and R W Busuttil
The significance of tumor necrosis factor (TNF) levels for rejection of joint allograft.
April 1997, Journal of reconstructive microsurgery,
D K Imagawa, and J M Millis, and P Seu, and K M Olthoff, and J Hart, and E Wasef, and R A Dempsey, and S Stephens, and R W Busuttil
Anti-class II antibody production prolongs renal allograft survival.
January 1989, Pathology and immunopathology research,
D K Imagawa, and J M Millis, and P Seu, and K M Olthoff, and J Hart, and E Wasef, and R A Dempsey, and S Stephens, and R W Busuttil
Anti-T12 monoclonal antibody therapy of acute renal allograft rejection.
February 1987, Transplantation proceedings,
D K Imagawa, and J M Millis, and P Seu, and K M Olthoff, and J Hart, and E Wasef, and R A Dempsey, and S Stephens, and R W Busuttil
Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha).
March 1990, Circulatory shock,
D K Imagawa, and J M Millis, and P Seu, and K M Olthoff, and J Hart, and E Wasef, and R A Dempsey, and S Stephens, and R W Busuttil
Lung allograft rejection: role of tumor necrosis factor-alpha and interleukin-6.
February 1993, Chest,
Copied contents to your clipboard!